Eli Lilly and Company (NYSE:LLY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Eli Lilly and Company (NYSE:LLY) has been assigned a consensus recommendation of “Moderate Buy” from the nineteen analysts that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $977.35.

A number of analysts have recently weighed in on the company. Berenberg Bank upped their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Truist Financial reissued a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Finally, Barclays lifted their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $921.49 on Monday. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The stock has a market capitalization of $875.79 billion, a price-to-earnings ratio of 135.71, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The company has a 50-day simple moving average of $895.06 and a two-hundred day simple moving average of $838.73.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 58,749 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $915.26, for a total transaction of $53,770,609.74. Following the sale, the insider now directly owns 97,308,620 shares of the company’s stock, valued at approximately $89,062,687,541.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 425,000 shares of company stock valued at $394,455,351. 0.13% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently made changes to their positions in the stock. Capital Planning LLC bought a new position in Eli Lilly and Company during the first quarter worth $262,000. CHURCHILL MANAGEMENT Corp bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $6,916,000. M&G Plc bought a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $8,896,000. IPG Investment Advisors LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $351,000. Finally, HighPoint Advisor Group LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at approximately $9,878,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.